Akorn, Inc. (NASDAQ:AKRX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other analysts have also issued reports on AKRX. Zacks Investment Research lowered Akorn from a “hold” rating to a “sell” rating in a report on Tuesday, February 28th. Royal Bank Of Canada set a $21.00 target price on Akorn and gave the stock a “hold” rating in a report on Thursday, March 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $24.00 target price on shares of Akorn in a report on Friday, March 3rd. Vetr lowered Akorn from a “strong-buy” rating to a “buy” rating and set a $27.00 target price on the stock. in a report on Monday, March 6th. Finally, Deutsche Bank AG lowered Akorn from a “buy” rating to a “hold” rating and dropped their target price for the stock from $28.00 to $24.00 in a report on Monday, March 6th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $30.55.

Analyst Recommendations for Akorn (NASDAQ:AKRX)

Akorn (AKRX) remained flat at $33.53 during midday trading on Friday. The stock had a trading volume of 2,472,890 shares. Akorn has a 52-week low of $17.61 and a 52-week high of $35.40. The company’s 50 day moving average price is $33.26 and its 200-day moving average price is $25.89. The firm has a market capitalization of $4.18 billion, a price-to-earnings ratio of 22.89 and a beta of 1.42.

COPYRIGHT VIOLATION WARNING: “Akorn, Inc. (AKRX) Lifted to Buy at BidaskClub” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/06/24/akorn-inc-akrx-lifted-to-buy-at-bidaskclub.html.

Institutional investors have recently bought and sold shares of the stock. NEXT Financial Group Inc increased its position in Akorn by 990.9% in the first quarter. NEXT Financial Group Inc now owns 3,000 shares of the company’s stock valued at $100,000 after buying an additional 2,725 shares during the last quarter. Meadow Creek Investment Management LLC increased its position in Akorn by 8.3% in the first quarter. Meadow Creek Investment Management LLC now owns 4,368 shares of the company’s stock valued at $105,000 after buying an additional 336 shares during the last quarter. Glen Harbor Capital Management LLC increased its position in Akorn by 8.3% in the first quarter. Glen Harbor Capital Management LLC now owns 5,304 shares of the company’s stock valued at $128,000 after buying an additional 408 shares during the last quarter. LS Investment Advisors LLC increased its position in Akorn by 21.8% in the first quarter. LS Investment Advisors LLC now owns 7,850 shares of the company’s stock valued at $189,000 after buying an additional 1,407 shares during the last quarter. Finally, Global Financial Private Capital LLC purchased a new position in Akorn during the first quarter valued at approximately $203,000. 76.94% of the stock is currently owned by institutional investors.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.